Core Scientific (CORZ) Common Equity (2020 - 2026)

Core Scientific (CORZ) has 7 years of Common Equity data on file, last reported at -$1.3 billion in Q1 2026.

• Quarterly Common Equity fell 322.8% year-over-year to -$1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 billion (down 322.8% YoY) and the FY2025 annual result came in at -$962.7 million, down 2.09% from the prior year.
• Common Equity fell to -$1.3 billion in Q1 2026 per CORZ's latest filing, from -$962.7 million in the prior quarter.
• The five-year high for Common Equity was $1.1 billion in Q1 2022, with the low at -$1.3 billion in Q1 2026.
• Average Common Equity over 5 years is -$522.9 million, with a median of -$418.7 million recorded in 2023.
• Year-over-year, Common Equity soared 1059.68% in 2022 and plunged 673.39% in 2023.
• Core Scientific's Common Equity stood at -$409.3 million in 2022, then tumbled by 45.83% to -$596.9 million in 2023, then sank by 57.98% to -$943.0 million in 2024, then decreased by 2.09% to -$962.7 million in 2025, then plunged by 35.62% to -$1.3 billion in 2026.
• Business Quant data shows CORZ's Common Equity at -$1.3 billion in Q1 2026, -$962.7 million in Q4 2025, and -$1.3 billion in Q3 2025.